Research programme: cancer therapeutics - FORMA/Moffitt Cancer CenterAlternative Names: HDAC modulators - FORMA/Moffitt
Latest Information Update: 25 Sep 2014
At a glance
- Originator FORMA Therapeutics; H. Lee Moffitt Cancer Center and Research Institute
- Class Small molecules
- Mechanism of Action Histone deacetylase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer